NCT07051629View on ClinicalTrials.gov

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients

PHASE1RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

June 16, 2025

Primary Completion Date

January 15, 2027

Study Completion Date

March 15, 2027

Conditions
EpilepsyHealthy Volunteer
Interventions
BIOLOGICAL

SIF001

SIF001 intravenous infusion every two weeks

DRUG

Placebo

Placebo

Trial Locations (2)

32720

RECRUITING

Accel Research sites network, DeLand

48334

RECRUITING

Quest Research Institute, Farmington Hills

All Listed Sponsors
lead

Suninflam Inc

INDUSTRY